Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ORUVAIL vs LINZESS
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, leading to decreased inflammation, pain, and fever.
Linaclotide is a guanylate cyclase-C (GC-C) agonist that activates GC-C on the luminal surface of intestinal epithelial cells, increasing intracellular cyclic guanosine monophosphate (c GMP) levels. Elevated c GMP stimulates chloride and bicarbonate secretion into the intestinal lumen, increasing fluid secretion and accelerating gastrointestinal transit. Additionally, it reduces visceral pain by decreasing activity of pain-sensing nerves.
Rheumatoid arthritis,Osteoarthritis,Ankylosing spondylitis,Acute painful shoulder (bursitis/tendinitis),Acute gouty arthritis,Juvenile idiopathic arthritis (off-label),Dysmenorrhea (off-label)
Treatment of irritable bowel syndrome with constipation (IBS-C) in adults,Treatment of chronic idiopathic constipation (CIC) in adults,Off-label: Treatment of constipation-predominant IBS in pediatric patients (limited data)
100 to 200 mg orally twice daily
72 mcg to 290 mcg orally once daily on an empty stomach at least 30 minutes before the first meal of the day.
5-9 hours (terminal elimination half-life); in elderly or renal impairment, may extend up to 20 hours; clinical context: dosing adjustments recommended in renal impairment.
Terminal half-life is 6.6 hours (range 4 – 12 h) in healthy subjects; not prolonged in renal or hepatic impairment.
Primarily hepatic via CYP2C9; undergoes extensive first-pass metabolism. Major metabolites include hydroxylated and carboxylated derivatives.
Linaclotide is minimally absorbed systemically and is metabolized within the gastrointestinal tract to its active peptide. No significant hepatic metabolism occurs; the primary route of elimination is fecal excretion as the active peptide.
Primarily renal excretion of metabolites (60-80%) with less than 1% unchanged drug; biliary/fecal excretion accounts for 20-40%.
Primarily fecal (95%) as intact drug; renal excretion accounts for <1%.
99% bound primarily to albumin.
Approximately 94% bound to human serum albumin.
0.1-0.2 L/kg; indicates low tissue distribution consistent with extensive protein binding.
Mean Vd is 4.4 L/kg, indicating extensive extravascular distribution into tissues.
Oral: 80-100% (immediate-release); topical: approximately 5% systemic absorption.
Oral bioavailability is approximately 4% due to extensive first-pass metabolism and low systemic absorption.
GFR 30-89 m L/min: no adjustment; GFR <30 m L/min: contraindicated
No dose adjustment required for mild to moderate renal impairment. Not studied in severe renal impairment or end-stage renal disease; use cautiously.
Child-Pugh A: no adjustment; Child-Pugh B or C: contraindicated
No dose adjustment required for mild to moderate hepatic impairment (Child-Pugh A or B). Not recommended in severe hepatic impairment (Child-Pugh C) due to lack of data.
Not recommended for use in pediatric patients
For functional constipation in pediatric patients: 72 mcg orally once daily for ages 6-17 years. Safety and efficacy not established below 6 years.
Initiate at lowest effective dose (100 mg/day); monitor renal function and gastrointestinal bleeding risk
No specific dose adjustment; start at 72 mcg daily. Monitor for diarrhea and electrolyte disturbances, especially in patients >65 years.
Nonsteroidal anti-inflammatory drugs (NSAIDs) cause an increased risk of serious cardiovascular thrombotic events, including myocardial infarction and stroke, which can be fatal. This risk may increase with duration of use. Patients with cardiovascular disease or risk factors for cardiovascular disease may be at greater risk. Oruvail is contraindicated for the treatment of peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery.
WARNING: RISK OF SERIOUS DEHYDRATION IN PEDIATRIC PATIENTS LESS THAN 2 YEARS OF AGE. Linaclose is contraindicated in pediatric patients up to 6 years of age. In young juvenile mice, linaclotide caused deaths due to dehydration; this risk was highest in mice less than 3 weeks of age (approximately equivalent to human pediatric patients less than 2 years of age). Use LINZESS in pediatric patients from 6 to less than 18 years of age only for the treatment of functional constipation (FC) and after evaluating the risk of dehydration and ensuring adequate fluid intake.
Cardiovascular thrombotic events; gastrointestinal bleeding, ulceration, and perforation; hypertension; congestive heart failure; renal toxicity; anaphylactoid reactions; serious skin reactions; hematologic toxicity; use with caution in patients with asthma, pre-existing renal impairment, or hepatic impairment.
Risk of serious dehydration in pediatric patients less than 2 years of age; contraindicated in patients up to 6 years of age.,Diarrhea: May cause severe diarrhea, especially during the first few weeks of treatment; if severe, discontinue use and rehydrate.,Do not use in patients with known or suspected mechanical gastrointestinal obstruction.
Hypersensitivity to ketoprofen or any component of the formulation; history of asthma, urticaria, or other allergic-type reactions after taking aspirin or other NSAIDs; peri-operative pain in the setting of coronary artery bypass graft (CABG) surgery; advanced renal disease; active GI bleeding or ulceration.
Pediatric patients up to 6 years of age (risk of serious dehydration).,Known or suspected mechanical gastrointestinal obstruction.,Hypersensitivity to linaclotide or any component of the formulation.
Take with food or milk to minimize gastrointestinal irritation. Avoid alcohol as it increases risk of GI bleeding. No significant food-drug interactions; however, high-fat meals may delay absorption but does not affect overall bioavailability.
Take on an empty stomach; avoid taking with food as food reduces absorption and efficacy.
First trimester: Avoid; associated with increased risk of cardiac defects and gastroschisis (OR 1.21-3.08). Second trimester: Caution; NSAIDs may cause oligohydramnios. Third trimester: Contraindicated; risk of premature ductus arteriosus closure and persistent pulmonary hypertension.
Linzess (linaclotide) is a guanylate cyclase-C agonist. Animal studies (rats, rabbits) at doses up to 800 mcg/kg/day showed no evidence of teratogenicity. There are no adequate and well-controlled studies in pregnant women. Based on animal data, the risk of major birth defects is low, but due to lack of human data, use only if clearly needed. First trimester: No known specific risk. Second and third trimesters: No known specific risk. No placental transfer data available; linaclotide is a large peptide with minimal systemic absorption, likely negligible fetal exposure.
Minimal excretion in breast milk (M/P ratio not reported). Use with caution; may cause adverse effects in neonates. Consider alternative analgesics.
No human data on linaclotide excretion in breast milk. Animal studies show low levels in rat milk with M/P ratio approximately 0.1-0.2. Due to minimal systemic absorption after oral administration, excretion into human milk is expected to be negligible. However, caution is advised. No adverse effects observed in nursing pups in animal studies. Consider benefits vs risks.
No dose adjustment recommended but avoid in 3rd trimester. Use lowest effective dose for shortest duration in 1st and 2nd trimesters.
No pharmacokinetic data on linaclotide in pregnancy. Due to minimal systemic absorption, significant pharmacokinetic changes are unlikely. No dose adjustment recommended in pregnancy. Standard dosing for chronic idiopathic constipation or irritable bowel syndrome with constipation (145 mcg or 290 mcg once daily) may be used if clinically indicated. Use caution in third trimester if risk of dehydration due to diarrhea.
Oruvail (ketoprofen extended-release) is an NSAID with analgesic, anti-inflammatory, and antipyretic effects. Due to its extended-release formulation, it should not be crushed or chewed. Use with caution in patients with renal impairment, history of GI bleeding, or cardiovascular disease. Monitor renal function and blood pressure periodically. It inhibits platelet aggregation similarly to aspirin but is reversible. May mask signs of infection.
Initiate at 290 mcg daily for IBS-C; 145 mcg daily for CIC; take on empty stomach at least 30 minutes before first meal; capsules must be swallowed whole; clinical response may take 2-4 weeks; contraindicated in patients with known or suspected mechanical GI obstruction; avoid in pediatric patients less than 2 years of age due to risk of serious diarrhea and dehydration.
Take exactly as prescribed; do not crush or chew the capsules.,Take with food or milk to reduce stomach upset.,Avoid alcohol and other NSAIDs (including over-the-counter ibuprofen or naproxen).,Report any signs of GI bleeding (black/tarry stools, vomiting blood), unexplained weight gain, edema, or worsening kidney function (decreased urination).,May cause dizziness or drowsiness; avoid driving until you know how it affects you.,Do not use if you have a history of asthma, hives, or allergic reaction to aspirin or NSAIDs.,Inform all healthcare providers that you are taking this medication, especially before surgery.
Take LINZESS at least 30 minutes before your first meal of the day on an empty stomach.,Swallow capsules whole; do not crush, chew, or open them.,Do not take LINZESS if you have a bowel blockage (intestinal obstruction).,Common side effects include diarrhea, abdominal pain, and gas; severe diarrhea may occur, especially in children under 2 years.,Tell your doctor if you have severe or persistent diarrhea, or if you experience symptoms of dehydration.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ORUVAIL vs LINZESS, answered by our medical review team.
ORUVAIL is a Nonsteroidal Anti-inflammatory Drug (NSAID) that works by Nonsteroidal anti-inflammatory drug (NSAID) that inhibits cyclooxygenase (COX-1 and COX-2), thereby reducing prostaglandin synthesis, leading to decreased inflammation, pain, and fever.. LINZESS is a Guanylate Cyclase-C Agonist that works by Linaclotide is a guanylate cyclase-C (GC-C) agonist that activates GC-C on the luminal surface of intestinal epithelial cells, increasing intracellular cyclic guanosine monophosphate (c GMP) levels. Elevated c GMP stimulates chloride and bicarbonate secretion into the intestinal lumen, increasing fluid secretion and accelerating gastrointestinal transit. Additionally, it reduces visceral pain by decreasing activity of pain-sensing nerves.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ORUVAIL and LINZESS depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ORUVAIL is: 100 to 200 mg orally twice daily. The standard adult dose of LINZESS is: 72 mcg to 290 mcg orally once daily on an empty stomach at least 30 minutes before the first meal of the day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ORUVAIL and LINZESS in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ORUVAIL is classified as Category C. First trimester: Avoid; associated with increased risk of cardiac defects and gastroschisis (OR 1.21-3.08). Second trimester: Caution; NSAIDs may cause oligohydramnios. Third trime. LINZESS is classified as Category C. Linzess (linaclotide) is a guanylate cyclase-C agonist. Animal studies (rats, rabbits) at doses up to 800 mcg/kg/day showed no evidence of teratogenicity. There are no adequate and. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.